The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.
Roswell Park Is First Site in Region Named a Resource for Patients With Rare Genetic DiseaseFebruary 17th 2021
Those diagnosed with von Hippel-Lindau disease have a resource for that complete and coordinated care in Roswell Park Comprehensive Cancer Center, which was recently named a VHL Clinical Care Center by the VHL Alliance.
VHL Disease: Monitoring Is Imperative, But Research Efforts Are Gaining Ground
VHL disease is defined as a rare, inherited disorder that causes tumors and cysts to grow in specific areas of the body, including the brain, spinal cord, eyes, inner ear, adrenal glands, pancreas, kidney, and reproductive tract.
Beti-Cel Results in Impressive Activity in Pediatric Transfusion-Dependent Beta-ThalassemiaFebruary 10th 2021
February 10, 2021 - Treatment with the investigative gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients less than 18 years of age with transfusion-dependent beta-thalassemia with a median average hemoglobin of 11.3 g/dL.
Surge of New Drugs Fuels Optimism in Pediatric Oncology
The landscape for pediatric oncology drugs expanded dramatically last year, with 8 new drugs or indications specifically approved for children compared with just 47 for treatment and supportive care products from the early 1950s through 2019.
Pembrolizumab Approaches EU Approval for Expanded Indication in Relapsed/Refractory Hodgkin LymphomaFebruary 1st 2021
February 1, 2020 - The European Medicines Agency’s Committee of Medicinal Products for Human Use has recommended a label expansion for pembrolizumab for use as a single agent in adult and pediatric patients aged 3 years and older with relapsed/refractory classical Hodgkin lymphoma for whom autologous stem cell transplant has failed or following at least 2 previous therapies when ASCT is not an option.
Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma
December 23, 2020 — Findings from the International, Prospective ALCL-Relapse trial showed that allogeneic SCT after reinduction chemotherapy can lead to survival improvements in children and adolescents with high-risk relapsed or refractory anaplastic large cell lymphoma, provide more insight into how to treat this population.
Experts Call for Increased Awareness of Existing Racial Disparities in RCC, Other MalignanciesSeptember 24th 2020
Despite the numerous reports detailing racial differences in cancer outcomes and care over the years, the reasons underlying these disparities continue to be under deep exploration.
Stronger Racial and Ethnic Minority Presence Is Needed in Clinical Cancer TrialsAugust 12th 2020
Numerous analyses conducted over the past few years have underscored a serious issue in clinical cancer trials that needs to be addressed: a lack of racial and ethnic diversity among participants.
FDA Issues Complete Response Letter for Pedmark for Prevention of Cisplatin-Induced Ototoxicity in Solid TumorsAugust 11th 2020
The FDA has issued a complete response letter to Fennec Pharmaceuticals regarding its new drug application for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.
FDA Grants Pedmark Priority Review for Prevention of Cisplatin-Induced Ototoxicity in Solid TumorsAugust 7th 2020
The FDA has granted a priority review designation to a new drug application for a unique formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.
FDA Approval Sought for Omburtamab in Pediatric Metastatic NeuroblastomaAugust 6th 2020
The biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for use in pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been submitted to the FDA under the agency’s Rolling Review process.
FDA Sets Review Date for Remestemcel-L for Steroid-Refractory Pediatric Acute GVHDJuly 21st 2020
The FDA’s Oncologic Drugs Advisory Committee has scheduled a date to review data supporting the biologics license application for remestemcel-L as a treatment for children with steroid-refractory acute graft versus host disease.
FDA Grants Naxitamab Priority Review for Relapsed/Refractory High-Risk NeuroblastomaJune 3rd 2020
The FDA has granted a priority review designation to a biologics license application for the investigational, humanized monoclonal antibody naxitamab (Danyelza) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.
Using a Multinational Pediatric Cancer Registry Helps to Improve PFS in High-Risk PatientsMay 29th 2020
The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.
Higher Anthracycline Doses Linked to Breast Malignancy Risk in Childhood Cancer SurvivorsJuly 5th 2019
Higher doses of anthracyclines are associated with increased risk of breast cancer in women who survived childhood cancer, regardless of whether they have mutations that predispose them to cancer.
Dr. van Tilburg on Larotrectinib in TRK+ Pediatric CancersJuly 2nd 2019
Cornelis M. van Tilburg, MD, PhD, pediatric oncologist, Hopp Children’s Cancer Center Heidelberg, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive cancers who have brain metastases or primary central nervous system tumors.
Larotrectinib Effective in TRK+ Pediatric Cancers and CNS Tumors
The efficacy of larotrectinib is supported in distinct patient populations with TRK fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.
Dr. Sweetenham on Unanswered Questions With CAR T-Cell Therapy in Pediatric ALLJune 1st 2019
John Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.
Pediatric Precision Medicine Approach Proven Possible in Pediatric MATCH Trial
About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.